EP1423693A4 - Kombinationstherapie mit erythropoetin und anti-tumornekrose-faktor-alpha - Google Patents

Kombinationstherapie mit erythropoetin und anti-tumornekrose-faktor-alpha

Info

Publication number
EP1423693A4
EP1423693A4 EP01959479A EP01959479A EP1423693A4 EP 1423693 A4 EP1423693 A4 EP 1423693A4 EP 01959479 A EP01959479 A EP 01959479A EP 01959479 A EP01959479 A EP 01959479A EP 1423693 A4 EP1423693 A4 EP 1423693A4
Authority
EP
European Patent Office
Prior art keywords
erythropoietin
combination therapy
necrosis factor
tumor necrosis
factor alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01959479A
Other languages
English (en)
French (fr)
Other versions
EP1423693A1 (de
Inventor
Loretta Itri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1423693A1 publication Critical patent/EP1423693A1/de
Publication of EP1423693A4 publication Critical patent/EP1423693A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP01959479A 2001-08-02 2001-08-02 Kombinationstherapie mit erythropoetin und anti-tumornekrose-faktor-alpha Withdrawn EP1423693A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/024384 WO2003012432A1 (en) 2001-08-02 2001-08-02 Erythropoietin and anti-tumor necrosis factor alpha combination therapy

Publications (2)

Publication Number Publication Date
EP1423693A1 EP1423693A1 (de) 2004-06-02
EP1423693A4 true EP1423693A4 (de) 2006-06-07

Family

ID=21742749

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01959479A Withdrawn EP1423693A4 (de) 2001-08-02 2001-08-02 Kombinationstherapie mit erythropoetin und anti-tumornekrose-faktor-alpha

Country Status (4)

Country Link
EP (1) EP1423693A4 (de)
JP (1) JP2004537569A (de)
CA (1) CA2456177A1 (de)
WO (1) WO2003012432A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101966183A (zh) * 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
GR1005808B (el) * 2006-11-27 2008-02-06 Bionature E.A. Limited Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010743A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
WO2002036152A1 (en) * 2000-10-31 2002-05-10 Amgen Inc. Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010743A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
WO2002036152A1 (en) * 2000-10-31 2002-05-10 Amgen Inc. Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEMETRI G D ET AL: "QUALITY-OF-LIFE BENEFIT IN CHEMOTHERAPY PATIENTS TREATED WITH EPOETIN ALFA IS INDEPENDENT OF DISEASE RESPONSE OR TUMOR TYPE: RESULTS FROM A PROSPECTIVE COMMUNITY ONCOLOGY STUDY", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 16, no. 10, October 1998 (1998-10-01), pages 3412 - 3425, XP009031711, ISSN: 0732-183X *
See also references of WO03012432A1 *
WOLCHOK J D ET AL: "PROPHYLACTIC RECOMBINANT EPOETIN ALFA MARKEDLY REDUCES THE NEED FOR BLOOD TRANSFUSION IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH BIOCHEMOTHERAPY", CYTOKINES, CELLULAR AND MOLECULAR THERAPY, MARTIN DUNITZ PUBLISHERS, LONDON, GB, vol. 5, no. 4, December 1999 (1999-12-01), pages 205 - 206, XP009031732, ISSN: 1368-4736 *

Also Published As

Publication number Publication date
JP2004537569A (ja) 2004-12-16
EP1423693A1 (de) 2004-06-02
WO2003012432A1 (en) 2003-02-13
CA2456177A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
EP1463438A4 (de) Endomurale therapie
EG24356A (en) Antitumor compounds and methods
AU2002352903A8 (en) Mesoporous materials and methods
AU2003215460A8 (en) Cancer associated protein kinases and their uses
GB0126879D0 (en) Combination therapy
IL154553A0 (en) Urocortin-iii and uses thereof
EP1294949A4 (de) Menschlicher tumornekrosefaktor delta und epsilon
EP1401494A4 (de) Tumortherapie
GB0119025D0 (en) Compounds and their therapeutic use
AU2002335667A1 (en) Modified reoviral therapy
EP1423693A4 (de) Kombinationstherapie mit erythropoetin und anti-tumornekrose-faktor-alpha
GB0111496D0 (en) Therapeutic systems and methods
GB0115780D0 (en) Therapeutic molecules and uses thereof
HUP0401162A3 (en) Substituted c-furan-2-yl-methylamine and c-thiophen-2-yl-methylamine derivatives
AU2001281032A1 (en) Erythropoietin and anti-tumor necrosis factor alpha combination therapy
HK1048265A1 (zh) 聯合療法
EP1367333A4 (de) Wärmepumpe und entfeuchter
AU2002366364A8 (en) E2f and cancer therapy
EP1367123A4 (de) Neurotonin und dessen verwendung
EP1463511A4 (de) Kombinationskrebstherapie
GB2376943B (en) Compounds and their therapeutic use
AU2002348162A1 (en) Antiviral combination therapy and compositions
GB0111494D0 (en) Methods and therapeutic systems
AU2002321141A1 (en) Pyrimidinoxyalkylpiperazines and their therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060504

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20060427BHEP

Ipc: A61K 31/454 20060101ALI20060427BHEP

Ipc: A61K 31/52 20060101ALI20060427BHEP

Ipc: A61K 31/70 20060101ALI20060427BHEP

Ipc: A01N 43/04 20060101ALI20060427BHEP

Ipc: A01K 67/027 20060101ALI20060427BHEP

Ipc: A01K 67/033 20060101ALI20060427BHEP

Ipc: A01K 67/00 20060101ALI20060427BHEP

Ipc: G01N 33/00 20060101ALI20060427BHEP

Ipc: A61K 39/395 20060101ALI20060427BHEP

Ipc: A61K 38/17 20060101ALI20060427BHEP

Ipc: A61K 38/18 20060101AFI20060427BHEP

17Q First examination report despatched

Effective date: 20090202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090613